Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) – Leerink Swann issued their Q3 2018 earnings estimates for shares of Biohaven Pharmaceutical in a research report issued on Monday, November 12th. Leerink Swann analyst M. Goodman expects that the company will post earnings per share of ($1.24) for the quarter. Leerink Swann currently has a “Outperform” rating and a $50.00 price target on the stock. Leerink Swann also issued estimates for Biohaven Pharmaceutical’s Q4 2018 earnings at ($1.42) EPS, FY2018 earnings at ($5.99) EPS, FY2019 earnings at ($6.30) EPS, FY2020 earnings at ($6.90) EPS, FY2021 earnings at ($4.40) EPS and FY2022 earnings at $1.75 EPS.

Biohaven Pharmaceutical (NYSE:BHVN) last released its quarterly earnings data on Wednesday, November 14th. The company reported ($1.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.48).

Other equities research analysts also recently issued reports about the company. Piper Jaffray Companies set a $48.00 price objective on Biohaven Pharmaceutical and gave the company a “buy” rating in a report on Thursday, August 16th. Cantor Fitzgerald set a $55.00 target price on Biohaven Pharmaceutical and gave the stock a “buy” rating in a report on Thursday. William Blair reissued an “outperform” rating on shares of Biohaven Pharmaceutical in a report on Thursday. Canaccord Genuity reissued a “buy” rating and issued a $43.00 target price on shares of Biohaven Pharmaceutical in a report on Friday, August 17th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $48.00 target price on shares of Biohaven Pharmaceutical in a report on Friday, August 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $49.33.

NYSE BHVN opened at $34.25 on Thursday. The company has a market cap of $1.46 billion, a price-to-earnings ratio of -6.85 and a beta of 1.25. Biohaven Pharmaceutical has a 1-year low of $16.50 and a 1-year high of $44.28.

Hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc raised its position in Biohaven Pharmaceutical by 111.3% in the 1st quarter. Legal & General Group Plc now owns 5,626 shares of the company’s stock worth $145,000 after purchasing an additional 2,963 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Biohaven Pharmaceutical by 602.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 5,057 shares of the company’s stock worth $190,000 after purchasing an additional 4,337 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Biohaven Pharmaceutical during the 2nd quarter valued at $191,000. Quantitative Systematic Strategies LLC bought a new stake in shares of Biohaven Pharmaceutical during the 2nd quarter valued at $205,000. Finally, Shell Asset Management Co. bought a new stake in shares of Biohaven Pharmaceutical during the 3rd quarter valued at $205,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.

Featured Article: How Do You Make Money With Penny Stocks?

Earnings History and Estimates for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.